AtG Therapeutics completes a seed financing round raising more than half a million euros
AtG Therapeutics is a breakthrough player in the oncology field and a recently created spinoff from Bellvitge Biomedical Research Institute (IDIBELL) and Catalan Institute of Oncology (ICO). AtG is developing a new treatment to prevent anti-angiogenics resistance, currently in the preclinical phase, and a prototype of a patient selector. This project was supported by international…